Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives
- 1 October 1988
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 70 (2), 137-141
- https://doi.org/10.1111/j.1365-2141.1988.tb02454.x
Abstract
We have studied the in vitro effects of nucleoside inhibitors of reverse transcriptase on bone marrow myeloid and erythroid progenitor development. Both 3''-azido-3''-deoxythymidine (AZT) and 2'',3''-dideoxycytidine (DDC) potently inhibited in vitro haematopoiesis, while 2'',3''-dideoxyadenosine (DDA) was less inhibitory in this culture system. Studies of candidate antiretroviral agents in bone marrow culture may predict clinical toxicity as well as lead to strategies for combination therapy which minimize impairment of haematopoiesis.This publication has 7 references indexed in Scilit:
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.Proceedings of the National Academy of Sciences, 1987
- Suppression of in vitro haematopoiesis following human immunodeficiency virus infectionNature, 1987
- Development of Antiretroviral Therapy for the Acquired Immunodeficiency Syndrome and Related DisordersNew England Journal of Medicine, 1987
- Strategies for antiviral therapy in AIDSNature, 1987
- ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEXThe Lancet, 1986